Refractory adult onset Still's disease successfully treated with anakinra
Refractory adult onset Still's disease successfully treated with anakinra
复制标题
DOI：
10.1136/ard.2004.026617
复制
发表时间：
2005-04-01
影响因子：
27.4
通讯作者：
da Silva, JC
中科院分区：
文献类型：
--
作者：
Godinho, FMV;Santos, MJP;da Silva, JC
方法和结果我们在2000年4月1日至2002年10月1日期间治疗了168例RA患者，82%为女性，中位病程为10年（范围1-49）。入选标准为28个关节计数疾病活动评分（DAS 28）。3.5以及包括甲氨蝶呤在内的两种改善疾病的抗风湿药物的失败。筛选前5年患有心力衰竭或恶性肿瘤的患者被排除。在结核病警报后，6名开始接受英夫利西单抗治疗的患者接受了结核病筛查。所有患者均接受3 mg/kg初始英夫利西单抗治疗（第0、2、6周，随后每8周一次）。当反应不明显时-即，在随后两次情况下DAS 28与基线相比降低1.2，剂量可增加至7.5 mg/kg。中位治疗持续时间为0.86年（范围0-2.5）;中位输注次数为7次（范围1-18）。分别有92%和50%的患者使用甲氨蝶呤和泼尼松。
METHODS AND RESULTS We treated 168 patients with RA between 1 April 2000 and 1 October 2002, 82% female, with a median disease duration of 10 years (range 1–49). Inclusion criteria were 28 joint count Disease Activity Score (DAS28) of. 3.5 and failure of two disease modifying antirheumatic drugs, including methotrexate. Patients with heart failure or with a malignancy 5 years before screening were excluded. After the alert about tuberculosis, 6 patients starting with infliximab treatment were screened for that disease. All patients were treated with an initial infliximab dose of 3 mg/kg (weeks 0, 2, 6, and subsequently, every 8 weeks). When the response was insufficient—that is, a decrease in DAS28, 1.2 compared with baseline on two subsequent occasions, the dose could be increased to 7.5 mg/kg. The median duration of treatment was 0.86 years (range 0–2.5); the median number of infusions used was 7 (range 1–18). Methotrexate and prednisone were used by 92% and 50% of the patients, respectively.